Rhabdomyosarcoma of parameningeal sites

Jr Wharam M.D.

Research output: Contribution to journalArticle

Abstract

Rhabdomyosarcoma arising in the skull base has a feature of its natural history that is unique in oncology: by virtue of parameningeal location and invasive behavior, it can extend intracranially and produce neoplastic meningitis. The four anatomic sites with this potential are the nasopharynx/nasal cavity, the middle ear, the paranasal sinuses, and the infratemporal fossa/pterygopalatine space. Patients with these primary sites comprise 41% of patients with head and neck sites and 15% of all patients with rhabdomyosarcoma. Most are under 10 years old at diagnosis (72%) and are Intergroup Rhabdomyosarcoma Study (IRS) Clinical Group III (76%). IRS protocols over the last 20 years have lead to a gradual improvement in outcome while refining radiation treatment parameters to allow for restricted indications for (and then the elimination of) whole cranial radiotherapy ports. The current guidelines (Group III) are for a dosage of 1.8 Gy/d up to a total of 50.4 Gy using 2-cm margins around the gross tumor volume at diagnosis. The timing of radiotherapy in relation to combination chemotherapy is based on assessment of three risk factors that predict tumor access to the cranial subarachnoid space: skull base erosion, cranial nerve palsy, and intracranial extension. Patients with one or more factors begin radiotherapy concurrently with chemotherapy. The remaining one third of patients begin radio-therapy after induction chemotherapy (week 9). The 5-year failure-free survival rate for patients with Group III parameningeal rhabdomyosarcoma on IRS-III was 71%. In the absence of the three risk factors, 5-year survival was 97%. The local failure rate was 15%. Among patients who achieved a complete or partial response (IRS-III), 5% had contiguous (nonhematogenous) central nervous system failure. Late effects of radiotherapy in these young patients are protean and include growth inhibition, cataracts, impaired dentition and hearing, and facial bone asymmetry. The promise of improvement of the therapeutic ratio may be realized from treatment refinements, which include chemotherapy response-based portal reduction, hyperfractionation, and conformal radiation therapy.

Original languageEnglish (US)
Pages (from-to)212-216
Number of pages5
JournalSeminars in Radiation Oncology
Volume7
Issue number3
DOIs
StatePublished - 1997

Fingerprint

Rhabdomyosarcoma
radiation therapy
chemotherapy
Radiotherapy
skull
Skull Base
meningitis
paranasal sinuses
tumors
Pterygopalatine Fossa
system failures
Facial Asymmetry
Facial Bones
middle ear
cataracts
Cranial Nerve Diseases
Drug Therapy
Subarachnoid Space
central nervous system
Induction Chemotherapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology
  • Radiation

Cite this

Rhabdomyosarcoma of parameningeal sites. / Wharam M.D., Jr.

In: Seminars in Radiation Oncology, Vol. 7, No. 3, 1997, p. 212-216.

Research output: Contribution to journalArticle

Wharam M.D., Jr. / Rhabdomyosarcoma of parameningeal sites. In: Seminars in Radiation Oncology. 1997 ; Vol. 7, No. 3. pp. 212-216.
@article{d5a50356e914430384b821a6a9fc7dbf,
title = "Rhabdomyosarcoma of parameningeal sites",
abstract = "Rhabdomyosarcoma arising in the skull base has a feature of its natural history that is unique in oncology: by virtue of parameningeal location and invasive behavior, it can extend intracranially and produce neoplastic meningitis. The four anatomic sites with this potential are the nasopharynx/nasal cavity, the middle ear, the paranasal sinuses, and the infratemporal fossa/pterygopalatine space. Patients with these primary sites comprise 41{\%} of patients with head and neck sites and 15{\%} of all patients with rhabdomyosarcoma. Most are under 10 years old at diagnosis (72{\%}) and are Intergroup Rhabdomyosarcoma Study (IRS) Clinical Group III (76{\%}). IRS protocols over the last 20 years have lead to a gradual improvement in outcome while refining radiation treatment parameters to allow for restricted indications for (and then the elimination of) whole cranial radiotherapy ports. The current guidelines (Group III) are for a dosage of 1.8 Gy/d up to a total of 50.4 Gy using 2-cm margins around the gross tumor volume at diagnosis. The timing of radiotherapy in relation to combination chemotherapy is based on assessment of three risk factors that predict tumor access to the cranial subarachnoid space: skull base erosion, cranial nerve palsy, and intracranial extension. Patients with one or more factors begin radiotherapy concurrently with chemotherapy. The remaining one third of patients begin radio-therapy after induction chemotherapy (week 9). The 5-year failure-free survival rate for patients with Group III parameningeal rhabdomyosarcoma on IRS-III was 71{\%}. In the absence of the three risk factors, 5-year survival was 97{\%}. The local failure rate was 15{\%}. Among patients who achieved a complete or partial response (IRS-III), 5{\%} had contiguous (nonhematogenous) central nervous system failure. Late effects of radiotherapy in these young patients are protean and include growth inhibition, cataracts, impaired dentition and hearing, and facial bone asymmetry. The promise of improvement of the therapeutic ratio may be realized from treatment refinements, which include chemotherapy response-based portal reduction, hyperfractionation, and conformal radiation therapy.",
author = "{Wharam M.D.}, Jr",
year = "1997",
doi = "10.1016/S1053-4296(97)80005-7",
language = "English (US)",
volume = "7",
pages = "212--216",
journal = "Seminars in Radiation Oncology",
issn = "1053-4296",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Rhabdomyosarcoma of parameningeal sites

AU - Wharam M.D., Jr

PY - 1997

Y1 - 1997

N2 - Rhabdomyosarcoma arising in the skull base has a feature of its natural history that is unique in oncology: by virtue of parameningeal location and invasive behavior, it can extend intracranially and produce neoplastic meningitis. The four anatomic sites with this potential are the nasopharynx/nasal cavity, the middle ear, the paranasal sinuses, and the infratemporal fossa/pterygopalatine space. Patients with these primary sites comprise 41% of patients with head and neck sites and 15% of all patients with rhabdomyosarcoma. Most are under 10 years old at diagnosis (72%) and are Intergroup Rhabdomyosarcoma Study (IRS) Clinical Group III (76%). IRS protocols over the last 20 years have lead to a gradual improvement in outcome while refining radiation treatment parameters to allow for restricted indications for (and then the elimination of) whole cranial radiotherapy ports. The current guidelines (Group III) are for a dosage of 1.8 Gy/d up to a total of 50.4 Gy using 2-cm margins around the gross tumor volume at diagnosis. The timing of radiotherapy in relation to combination chemotherapy is based on assessment of three risk factors that predict tumor access to the cranial subarachnoid space: skull base erosion, cranial nerve palsy, and intracranial extension. Patients with one or more factors begin radiotherapy concurrently with chemotherapy. The remaining one third of patients begin radio-therapy after induction chemotherapy (week 9). The 5-year failure-free survival rate for patients with Group III parameningeal rhabdomyosarcoma on IRS-III was 71%. In the absence of the three risk factors, 5-year survival was 97%. The local failure rate was 15%. Among patients who achieved a complete or partial response (IRS-III), 5% had contiguous (nonhematogenous) central nervous system failure. Late effects of radiotherapy in these young patients are protean and include growth inhibition, cataracts, impaired dentition and hearing, and facial bone asymmetry. The promise of improvement of the therapeutic ratio may be realized from treatment refinements, which include chemotherapy response-based portal reduction, hyperfractionation, and conformal radiation therapy.

AB - Rhabdomyosarcoma arising in the skull base has a feature of its natural history that is unique in oncology: by virtue of parameningeal location and invasive behavior, it can extend intracranially and produce neoplastic meningitis. The four anatomic sites with this potential are the nasopharynx/nasal cavity, the middle ear, the paranasal sinuses, and the infratemporal fossa/pterygopalatine space. Patients with these primary sites comprise 41% of patients with head and neck sites and 15% of all patients with rhabdomyosarcoma. Most are under 10 years old at diagnosis (72%) and are Intergroup Rhabdomyosarcoma Study (IRS) Clinical Group III (76%). IRS protocols over the last 20 years have lead to a gradual improvement in outcome while refining radiation treatment parameters to allow for restricted indications for (and then the elimination of) whole cranial radiotherapy ports. The current guidelines (Group III) are for a dosage of 1.8 Gy/d up to a total of 50.4 Gy using 2-cm margins around the gross tumor volume at diagnosis. The timing of radiotherapy in relation to combination chemotherapy is based on assessment of three risk factors that predict tumor access to the cranial subarachnoid space: skull base erosion, cranial nerve palsy, and intracranial extension. Patients with one or more factors begin radiotherapy concurrently with chemotherapy. The remaining one third of patients begin radio-therapy after induction chemotherapy (week 9). The 5-year failure-free survival rate for patients with Group III parameningeal rhabdomyosarcoma on IRS-III was 71%. In the absence of the three risk factors, 5-year survival was 97%. The local failure rate was 15%. Among patients who achieved a complete or partial response (IRS-III), 5% had contiguous (nonhematogenous) central nervous system failure. Late effects of radiotherapy in these young patients are protean and include growth inhibition, cataracts, impaired dentition and hearing, and facial bone asymmetry. The promise of improvement of the therapeutic ratio may be realized from treatment refinements, which include chemotherapy response-based portal reduction, hyperfractionation, and conformal radiation therapy.

UR - http://www.scopus.com/inward/record.url?scp=0030837049&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030837049&partnerID=8YFLogxK

U2 - 10.1016/S1053-4296(97)80005-7

DO - 10.1016/S1053-4296(97)80005-7

M3 - Article

AN - SCOPUS:0030837049

VL - 7

SP - 212

EP - 216

JO - Seminars in Radiation Oncology

JF - Seminars in Radiation Oncology

SN - 1053-4296

IS - 3

ER -